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In 2014, two external quality assessment trials were performed on 13 test items grouped 
in four categories. The laboratories procured the materials for the first and second trials 
on 13 May 2014 and 11 November 2014, respectively. The trials were performed on 13 test 
items, including tumour markers, thyroid hormones, cardiac marker troponin (troponin T 
or troponin I), and procalcitonin as a new biomarker for immunoassay methods. The bone 
marker carboxy-terminal collagen crosslinks (CTX) has been replaced by procalcitonin this 
year because only a limited number of institutions used it. External quality surveys of the 
13 immunoassay test items with 8 control materials were performed as scheduled. The 13 
control materials included six tumour markers, alpha-fetoprotein, carcinoembryonic antigen, 
carcinoma antigen 125, carbohydrate antigen 19-9, human chorionic gonadotrophin, and 
prostate specific antigen, as well as five thyroid markers, thyroid hormone 3 (T3), T4, 
thyroid stimulating hormone, free T4, and thyroglobulin. This year, procalcitonin has been 
introduced as a new biomarker in addition to troponin, which was introduced last year. Five 
homemade pooled sera and three commercial control sera were used as survey materials. 
The MAS Tri-point Liquimmune level 3 (Medical Analysis Systems Inc., USA) was used for 
controls of thyroid hormones, while Elecsys PreciControl Varia and Elecsys PreciControl 
Troponin (Roche, Germany) were used for controls of the new biomarkers procalcitonin 
and troponin, respectively. In the external quality assessment by the Immunoassay 
Subcommittee, 712 institutions participated in the first trial survey (response rate 97.9%), 
while 715 participated in the second survey (response rate 97.9%). The quality of the 
participating laboratories seems to be continuously improving compared to the results of 
their peers. Additionally, this year procalcitonin has been introduced as a new biomarker 
instead of the CTX, which was used in 2013, while thyroglobulin and troponin-T/troponin-I, 
which were used for the 2013 samples, continue to be used in surveys by the Immunoassay 
Subcommittee.
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Table 2. Laboratories participating in the as sessment of immun-
oassay tests in 2014
Test marker
Participating laboratories
1st trial (%) 2nd trial (%)
Tumour markers 644 (92.4) 646 (92.3)
Thyroid markers 647 (92.8) 654 (93.4)
Cardiac markers
  Troponin T 74 (10.6) 75 (10.7)
  Troponin I 254 (36.4) 263 (37.6)
New biomarkers
  Procalcitonin 142 (20.4) 160 (22.9)
Results received 697 (100.0) 700 (100.0)
Total no. of institutions invited 712 715
Table 3. Current status of individual test markers used in the im-
munoassay test in clinical laboratories in 2014
Test marker
Participating laboratories
1st trial 2nd trial
Tumour markers
  Alpha-fetoprotein 644 646
  Carcinoembryonic antigen 552 554
  Carcinoma antigen 125 432 436
  Carbohydrate antigen 19-9 473 478
  Prostate specific antigen 532 538
  HCG 156 153
  β-HCG 4 6
Thyroid markers
  T3 562 566
  T4 146 135
  Free T4 629 635
  Thyroid stimulating hormone 647 654
  Thyroglobulin 70 71
Cardiac markers
  Troponin T 74 75
  Troponin I 254 263
New biomarkers
  Procalcitonin 142 160
Results received 697 700
Total no. of institutions invited 712 715
Abbreviations: HCG, human chorionic gonadotrophin; T, thyroid 
hormone.
Table 1. 2014 schema of external quality assessment in immunoassay testing
No. of laboratories invited Participating laboratories (%) Date of procurement of sera Date of results
1st trial 712 697 (97.9%) 13 May 2014 15 Jul 2014
2nd trial 715 700 (97.9%) 11 Nov 2014 26 Dec 2014
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Table 4. Control materials used for the immunoassay external quality assessment in 2014
Test marker Test item 1st trial 2nd trial












Cardiac markers Troponin T Specimen no. 7*, 8* (14-IA-7*, 8*) Specimen no. 15, 16 (14-IA-15, 16)
Troponin I
New biomarker Procalcitonin Specimen no. 5, 6 (14-IA-5, 6) Specimen no. 13, 14 (14-IA-13, 14)
Abbreviations: HCG, human chorionic gonadotrophin; T, thyroid hormone.
*Commercial sera: others were pooled sera prepared by the Immunoassay Subcommittee.
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Table 10. Immunoassays conducted using the human chorionic gonadotrophin marker (IU/L)
14-IA-1 14-IA-2 14-IA-09 14-IA-10
No. Mean* SD CV (%) No. Mean SD
CV 
(%) No. Mean SD
CV 




  Fluorescent  
    immunoassay†
5 103.61 11.33 10.93 5 14.96 2.34 15.62 4 144.97 7.07 4.88 4 22.71 2.95 13
  Chemilumi- 
    nescence
95 99.09 6.64 6.7 95 15.8 0.98 6.22 92 136.17 10.51 7.72 92 21.08 1.6 7.58
  Electrochemilu-
    minescence
55 87.07 4.32 4.96 55 13.63 0.78 5.72 56 120.18 4.84 4.03 56 18.47 0.91 4.91
155 155 152 152
Analyser
  Architect series 49 97.93 4.91 5.01 49 15.7 0.98 6.24 44 134.95 6.8 5.04 44 20.72 1.14 5.49
1 151.6 1 21.2
  ADVIA Centaur 
    XP/classic
23 107.55 5.13 4.77 23 16.01 1.03 6.42 24 145.86 6.63 4.55 24 22.06 1.48 6.73
  Access, Access II 4 89.05 2.29 2.57 4 15.13 0.32 2.12 6 122.78 8.51 6.93 6 19.97 2.33 11.65
  Beckman DXi 15 93.37 4.68 5.01 15 15.86 1.36 8.58 13 122.69 6.98 5.69 13 20.09 1.62 8.08
  VIDAS 5 103.61 11.33 10.93 5 14.96 2.34 15.62 4 144.97 7.07 4.88 4 22.71 2.95 13
  Immulite, 
    Immulite 200
4 100.6 3.13 3.11 4 16.25 0.71 4.39 4 142.93 10.83 7.58 4 23.23 1.92 8.26
  E170/e601/e602 43 88.63 2.63 2.97 43 13.89 0.5 3.56 46 121.06 3.56 2.94 46 18.66 0.71 3.78
  Elecsys 2010/
    e411
12 81.65 5.62 6.88 12 12.57 1.23 9.77 10 113.99 10.5 9.21 10 17.33 2.09 12.08
155 155 152 152
*Mean, SD, and %CV are of peer group (no.). †14-IA-1 represents the specimen no. used in the trial; it stands for 2014-immunoassay-no. 1 
specimen.   
Table 11. Immunoassays conducted using the β-human chorionic gonadotrophin marker (ng/mL)
14-IA-1 14-IA-2 14-IA-09 14-IA-10
No. Mean* SD CV (%) No. Mean SD
CV 
(%) No. Mean SD
CV 




  Fluorescent 
    immunoassay†
3 93.58 2.8 2.99 3 14.77 1.98 13.43 5 145.46 12.36 8.49 5 20.04 1.53 7.63
  Chemiluminescence 1 74.7 1 11.9 1 97.5 1 15.4
4 4 6 6
Analyser
  VIDAS 3 93.58 2.8 2.99 3 14.77 1.98 13.43 5 145.46 12.36 8.49 5 20.04 1.53 7.63
  VISTA 1 74.7 1 11.9 1 97.5 1 15.4
4 4 6 6
*Mean, SD, and %CV are of peer group (no.). †14-IA-1 represents the specimen no. used in the trial; it stands for 2014-immunoassay-no. 1 
specimen. 
200 J Lab Med Qual Assur 2015;37:190-208 www.jlmqa.org












































































































   
 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































201J Lab Med Qual Assur 2015;37:190-208www.jlmqa.org












































































































































































































































































































































































































































































































































































































































































































































































202 J Lab Med Qual Assur 2015;37:190-208 www.jlmqa.org






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































203J Lab Med Qual Assur 2015;37:190-208www.jlmqa.org


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































204 J Lab Med Qual Assur 2015;37:190-208 www.jlmqa.org

































































































































































































































































































































































































































205J Lab Med Qual Assur 2015;37:190-208www.jlmqa.org



































































































































































































































































































































































































































































































































































































































































































































































































































































































































206 J Lab Med Qual Assur 2015;37:190-208 www.jlmqa.org



































































































































































































































































































































































































































































































































































































































































































































































































207J Lab Med Qual Assur 2015;37:190-208www.jlmqa.org










1. Kim HS, Kim YL; Immunoassay Subcommittee, The 
Korean Association of Quality Assurance for Clinical 
Laboratories. Annual report on external quality as-
sessment of immunoassay testing in Korea (2013). J Lab 
Med Qual Assur 2014;36:171-89.
2. Kim HS, Kim YL, Park J, Kwon OH, Kim DA, Kim 
JQ, et al. Immunoassay external quality assessment of 
immunoassay subcommittee (2010). J Lab Med Qual 
Assur 2011;33(Suppl):S91-114.
3. Kim HS, Kim YL, Park J, Kwon OH, Kim DA, Kim JQ, 
et al. Annual report on external quality assessment in 
immunoassay in Korea (2009). J Lab Med Qual Assur 
2010;32:103-14.
4. Cha YJ, Kwon SY, Kim TY, Kim JR, Kim HS, Park MH, 
et al. Annual report on external quality assessment in 
immunoserology in Korea (2008). J Lab Med Qual Assur 
2009;31:49-72.
5. Kim HS, Kim YL, Lim HS, Park J, Chun HS, Shin S, 
et al. Annual report on external quality assessment of 
Immunoassay Subcommittee in Korean Clinical La boratory 
Survey (2007). J Lab Med Qual Assur 2008;30:111-32.
6. Kim HS, Kim YL, Lim HS, Chun HS, Shin S, Jung YS, 
et al. Annual report on external quality assessment of 
Immunoassay Subcommittee in Korean Clinical La boratory 
Survey (2006). J Lab Med Qual Assur 2007;29:99-119.
7. Kim HS. Immunoassay external quality control of 
immunoassays. J Lab Med Qual Assur 2003;25(S2): S387-
91.
8. Kim HS, Lim HS, Kwon OH, Kim DA, Kim YK, Kim YR, 
et al. Annual report on external quality assessment of 
immunoassay in Korea (2001). J Clin Pathol Qual Con-
trol 2002;24:83-94.
9. Kwon OH, Lim HS, Kim HS, Kim DA, Kim YK, Kim 
JQ, et al. Annual report on external quality assessment in 
immunoassay in Korea (2000). J Clin Pathol Qual Control 
2001;23:111-44.
10. Kim HS. Future trends of immunoassay EQA. J Clin 
Pathol Qual Control 2001;23:S275-6.
11. Bock JL. The new era of automated immunoassay. Am J 
Clin Pathol 2000;113:628-46. 
12. Ritchie RF. Immunoanalytical standardization: a global 
science. Scand J Clin Lab Invest Suppl 1991;205:3-10.
13. Whicher JT. Calibration is the key to immunoassay but 
the ideal calibrator is unattainable. Scand J Clin Lab 
Invest Suppl 1991;205:21-32.
14. Wood WG. “Matrix effects” in immunoassays. Scand J 
Clin Lab Invest Suppl 1991;205:105-12. 
15. Tahlan A, Barrowcliff e T, Das RG, Shin J, Wood D. WHO 
technical workshop on stability of reference materials 
for biological medicines and in vitro diagnostics, 
Geneva, Switzerland, 28-29 November 2005. Biologicals 
2007;35:361-5. 
16. Jenny RW, Jackson-Tarentino KY. Causes of unsatis-
factory performance in proficiency testing. Clin Chem 
2000;46:89-99. 
17. Kwon OH, Lim HS, Kim HS, Kim DU, Kim YK, Kim 
JQ, et al. Annual report on external quality assessment 
in immunoassay in Korea (1995). J Clin Pathol Qual 
Control 1996;18:95-117. 
18. Kim HS. Internal quality control of immunochemistry 
tests. J Clin Pathol Qual Control 1993;15:S147-51. 
19. Feldkamp CS, Carey JL. Standardization of immunoassay 
methodologies. In: Rose NR, Hamilton RG, Detrick B, 
editors. Manual of clinical laboratory immunology. 6th 
ed. Washington (DC): ASM Press, 2002: 1215-26. 
20. College of American Pathologists. Standards for 
laboratory accreditation: Laboratory Accreditation 
Program 1998 edition. http://www.cap.org (Accessed 
December 2, 2015). 
21. Miyai K, Price CP. Problems for improving performance 
in immunoassay. J Int Fed Clin Chem 1992;4:154-63. 
208 J Lab Med Qual Assur 2015;37:190-208 www.jlmqa.org
Hyon-Suk Kim et al • EQA of Immunoassay Tests
면역측정검사분과 신빙도조사 결과보고(2014)
김현숙 • 김영란 • 대한임상검사정도관리협회 면역측정검사분과위원회
연세대학교 의과대학 진단검사의학교실 
 
2014년도 면역측정검사분과에서는 2회에 걸쳐 각 8종씩, 총 16종의 관리물질을 1차 712기관, 2
차 715기관에 대해서 신빙도조사를 실시하였다. 1회와 2회째 모두 갑상선호르몬 검사용 관리물질
은 높은 결과치를 보이는 혈청을 수집하기 어려웠기 때문에 상품화된 제품을 구입하여 사용하였고, 
그 외의 관리물질은 자가제조 하였다. 결과 회신율은 1차와 2차 모두 97.9%이었다. 검사결과의 분
석 및 보고방법은 평균, 표준편차, 변이계수 등으로 분석하였으며, 참여 기관에서 사용하고 있는 방
법과 장비에 따라 기기별로 분류하여 peer group 결과를 분석하였다. 협회에서 전산화가 잘 되어 
있어서 우리 분과의 외부신빙도조사 결과 입력은 물론, 전체 방법과 기기별 통계, 그리고 협회 홈페
이지에서 인터넷을 이용하여 각 기관의 결과지 출력까지 가능하게 되었다. 현재 참여기관들에서 가
장 많이 사용되는 면역측정법은 자동화된 화학발광면역장비들이었는데, 이들 자동화 장비들이 대
개 고유 원리와 시약을 사용하고 있어서 서로 결과치가 다를 수 있고 정확한 결과를 위해서는 장비
와 사용자에 따른 정도관리가 지속적으로 필요한 것으로 판단되었다. 또한 지금까지와 마찬가지로 
전국적인 신빙도조사 사업 참여를 통해 검사의 질을 높여 나가야 할 것으로 생각되었다.
(J Lab Med Qual Assur 2015;37:190-208)
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